Biotech Values

[oc631]

In short, I would say the big business opportunity for HCV drugs—Asia included—will come during the next 10 years, not in the decades thereafter.

Not only are you overstating the abilities of drug companies and Asian governments to reach patient populations but you are handicapping the virus.